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Papillarythyroidcarcinomas(PTCs)withadiameter ≤1cmarereferred toaspapillary microcarcinomas(PTMCs).The prognostic
factors for PTMCs have not been deﬁned. Diﬀerent clinical and histopathologic variables were studied in 152 PTCs, including
74 PTMCs and 78 PTCs of larger size. We found that PTMCs are associated with less multifocality (P = .046) and bilaterality
(P = .003), fewer lymphadenectomies (P<. 001), and a higher rate of incidental tumours (P<. 001). Moreover, patients with
a low aggressive proﬁle were signiﬁcantly older than the remaining patients (54 ± 13.7 years versus 45.8 ± 13.1y e a r s ;P = .001).
In conclusion PTMCs show signiﬁcant diﬀerences compared to PTCs of larger size in the form of presentation. Furthermore, it is
possible that the classic risk factors, which are well validated in PTCs, such as age, must be cautiously interpreted in the current
increasing subgroup of PTMCs.
1.Introduction
It has been clearly demonstrated that there is an increasing
worldwideincidenceofpapillarythyroidcarcinomas(PTCs).
Itis uncertain whether this is areal phenomenon, orwhether
it is due to an increased rate of detection [1]. Practices
for management of thyroid diseases have changed over the
past few decades. The wide availability of ultrasound (US)
and ﬁne needle aspiration biopsy (FNAB) and the improved
accuracy of histopathologic examination of surgical speci-
mens have been suggested to be reasons for the increased
rateofdetection.Moreover,amongthenewcases,thehighest
incidence has been observed in the smallest tumors [2]. In
theUSA,49%oftheincreased incidenceofPTCsconsistedof
cancers measuring ≤1cm[3]. In Europe, Leenhardt et al. [4]
reported that the proportion of tumors of this size increased
from 18.4% between 1983 and 1987 to 43.1% between 1998
and 2001 [4]. Similar results have been conﬁrmed by other
authors worldwide [2, 5–8].
PTCs measuring ≤1cm are referred to as papillary
thyroid microcarcinomas (PTMCs) [9]. Although PTMCs
are not recognized as a speciﬁc entity in the tumour, node,
and metastasis (TNM) classiﬁcation, PTMCs are considered
a subset of PTCs that exhibit a more benign behavior.
PTMCs usually follow an indolent course and carry an
excellent prognosis. Distant metastases and mortality rates
are reported to be <0.5% for PTMCs [10]. Two large
series have recently conﬁrmed the excellent prognosis for
PTMCs in long-term followup [5, 11]. Nevertheless, some
authors suggest that there exist a subgroup of PTMCs
that can be aggressive, requiring therapeutic management
similar to larger tumors [12]. Thus, no agreement has
been reached about the optimal treatment of PTMCs. In
recent years, several clinical and histologic risk factors
for aggressiveness have been identiﬁed in PTMCs, such
as size ≤5mm, multifocality, capsular invasion, tumor
extensionbeyondtheparenchyma, lymphnodeinvolvement,
and the extent of primary surgery [12–17]. In contrast,
some studies have failed to identify independent prognostic
factors, arguing that to distinguish PTCs on the basis of
size alone may be clinically irrelevant [18, 19]. Because
PTMCs are being diagnosed with increasing frequency,
identiﬁcation of speciﬁc prognostic factors is of outmost
importance.2 Journal of Thyroid Research
In the present study, we describe the clinical and
pathologic presentation of PTMCs, compared with papillary
thyroid carcinomas of larger size (LPTCs). We have analyzed
the classic risk factors and studied the clinical and histologic
characteristics present at the time of diagnosis which were
associated with ahigher risk ofrecurrence inPTMCs, such as
multifocality,lymphnode metastases, and modeofdetection
(incidental versus nonincidental tumors).
2.Methods
P T M C sw e r ed e ﬁ n e da sP T C sm e a s u r i n g≤1cmingreatest
diameter.Modeofdetectionreferstoincidental(IPTMCs)or
nonincidental tumors (NIPTMCs). IPTMCs were identiﬁed
in patients undergoing surgery for reasons unrelated to a
thyroid malignancy, whereas patients with NIPTMCs under-
went thyroidectomy for suspected malignancies. Multifocal
disease was deﬁned when >1 focus of PTCs was found in
the thyroidectomy specimen. The following clinical variables
were considered in the analysis: patient age, mode of detec-
tion, and extent of disease. The histopathologic variables
after postoperative pathologic examination included the
maximum diameter of the primary tumour, multifocality,
bilaterality, extrathyroid extension, and lymph node metas-
tases. Patients with PTMCs discovered incidentally, without
multifocality, and without lymph node involvement were
considered at low risk for developing recurrences. The conﬁ-
dentiality of patient information was absolutely maintained.
Data are presented as the mean ± SD. Statistical analysis was
performed by Fisher’s exact test for univariate analysis and
by Student’s t-test to compare continuous variables between
groups. All tests were two-tailed. The levels of statistical
signiﬁcance arepresented aspvalues.Itwasassumed thatthe
observed diﬀerences were statistically signiﬁcant at a P<. 05
level.
3.Results
Between 2000 and 2009, 152 patients with PTCs were treated
in our institution. Among these cases, there were 74 (48.7%)
PTMCs and 78 (51.3%) LPTCs.
3.1. Microcarcinoma. The PTMC series included 59 females
and 15 males (the female-to-male ratio was approximately
3.9). The mean age at the time of diagnosis was 50.1 ±
13.2 years. Of the 74 cases, 67 (90.5%) underwent total
or near-total thyroidectomy, and only 7 (9.5%) underwent
lobectomies. The mean tumour size was 5.7 ± 2.6mm.
The pathology reports showed classic variant PTMCs in
64 patients (86%), and follicular variants in 10 patients
(14%). Multifocal disease was documented in 26 patients
(35.1%). The patients with multifocal disease were younger
than patients with a unique focus (45.9 ± 10.2 years versus
52.5 ± 14.2y e a r s ;P = .039). Contralateral involvement
was observed in 7 of 26 patients (27%) with multifocal
tumors. Regional lymph nodes were removed in 24 patients
(32.4%); of these, 12 (50%) had nodal tumor involve-
ment.
Overall,72.2%oftumors(52of72)presentedasIPTMCs
(no information was available in 2 cases). In the other 20
cases (27.8%), PTMCs were diagnosed by preoperative US-
guided FNABs. In patients with IPTMCs, the indications for
surgery were as follows: 29 nontoxic multinodular goiters,
7 toxic multinodular goiters, and 16 solitary nodules. The
diﬀerence in mean tumour size was statistically signiﬁcant
among the IPTMCs (5 ± 2.3mm) and NIPTMCs (7.6 ±
2.6mm; P<. 001). Multifocality was present in 13 (65%)
of 20 patients classiﬁed as NIPTMCs, whereas multifocality
was present in only 11 (21%) of 52 patients with IPTMCs
(P<. 001).
3.2. Larger Tumours. Tumors >1cm occurred in 62 females
and 16 males (the female-to-male ratio was approximately
3.9). The mean age at the time of diagnosis was 46.2 ± 14.1
years. The primary surgical treatment consisted of total or
near-total thyroidectomies in 76 patients and lobectomies
in 2 patients. The mean tumor size was 25.21 ± 11.8mm.
The pathology reports showed classic variant LPTCS in 54
patients (69.2%), follicular variant LPTCs in 21 patients
(26.9%), and one case each of columnar cell, cribiform-
morular variant, and clear cell LPTCs. In this group,
multifocality was found in 39 (50%) samples. The age at
presentation was not diﬀerent in patients with and without
multifocality. Contralateral involvement occurred in 25 of
39 patients (64%) with multifocal tumours. Lymph node
dissection was performed in 60 patients (77%); of these, 36
patients (60%) had nodal tumor involvement.
Only 11 (15.5%) of 71 cases were classiﬁed as incidental
tumors (no information was available in 7 cases). Of the
indications for surgery were as follows: 7 nontoxic multin-
odular goiters, 3 solitary nodules, and 1 toxic multinodular
goiter. Neither tumor size nor multifocality was signiﬁcantly
diﬀerent among the incidental and nonincidental LPTCs.
3.3. PTMCs versus LPTCs. Table 1 shows the characteristics
of both groups. Age and gender were not statistically
diﬀerent between the two groups of patients. However,
based on the mode of presentation, patients with IPTMCs
were signiﬁcantly older than patients with incidental LPTCs
(51.9 ± 13.5 years versus 41.4 ± 7.95 years; P = .016).
Moreover, apart from size (P<. 0001), patients with PTMCs
presented with multifocality (P = .046) and bilaterality (P =
.003) less often, fewer lymphadenectomies (P<. 001), and a
higher rate of incidental tumours (P<. 001). In contrast, in
patientsin whom the lymph nodeswere removed, there were
no diﬀerences in the frequency of nodal metastases.
3.4. Aggressive Cases. Among all the 152 patients with PTCs,
40 patients (26.3%) in whom PTMCs were discovered
incidentally, without multifocality, and without lymph node
involvement, were considered at a low risk for developing
recurrences. These patientswith a low aggressive proﬁle were
signiﬁcantly older than the rest of the patients (54 ± 13.7
y e a r sv e r s u s4 5 .8 ± 13.1y e a r s ;P = .001). Moreover, the low
aggressive proﬁle was observed in 28 (36.8%) of 76 patients
>45 years of age and in 12 (17.9%) of 67 patients <45 yearsJournal of Thyroid Research 3
Table 1:Diﬀerences between caseswithpapillary thyroidmicrocar-
cinomas (PTMCs) from those with papillary thyroid carcinomas of
larger size (LPTCs).
PTMC (n = 74) LPTC (n = 78) P
Gender (female/male) 15/59
(79.7%/20.3%)
16/62
(79.5%/20.5%) ns
Age (y) 50.17± 13.22 46.29 ±14.12 ns
Size (mm) 5.7 ± 2.62 5 .2 ±11.8 <.001
Multifocality 26/74 (35.1%) 39/78 (50%) .046
Lymphadenectomies 24/74 (32.4%) 60/78 (77%) <.001
Lymph M1 12/24 (50%) 36/60 (60%) ns
Incidental 52/72 (72.2%) 11/72 (15.2%) <.001
>60years 45–60years <45years
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Figure 1: Patients with a low aggressive proﬁle are signiﬁcantly
older than patients with a high aggressive proﬁle.
ofage (P = .006).Finally, patients ≥60 years ofage had more
cases with low aggressiveness compared to patients <45years
of age (P = .002), and to patients between 45 and 60 years of
age (P = .05). This data is shown in Figure 1.
4.Discussion
PTMC is deﬁned as PTC measuring ≤1cm in size [9].
This variant is also known as occult papillary carcinoma,
latent papillary carcinoma, small papillary carcinoma, and
papillary microtumor[20].Thecurrentincrease inincidence
of PTC worldwide is mainly attributed to the corresponding
increase in the diagnosis of PTMCs. In most recent series,
especially the series that have analyzed cases from the last
decade, PTMCs comprise nearly one-half of all the cases
of PTCs [2, 3, 8, 21, 22]. Our series conﬁrms this data.
PTMCs are considered a subset of PTCs that exhibit a
more benign behavior. Distant metastases and mortality
rates are reported to be <0.5% in patients with PTMCs [10].
Hay et al. [5]r e p o r t e dn od i ﬀerence between the observed
number of deaths and the expected number of deaths in a
cohort of 900 cases. Appetecchia et al. [23] reported that the
outcome of PTMCs was favorable, even in the presence of
lymph node metastases and local invasion. In contrast, some
authors have suggested that there exist a subset of PTMCs
that can be aggressive, requiring therapeutic management
similar to larger PTCs [6, 12]. Thus, no agreement has
been reached about the optimal treatment of PTMCs. Some
authorsrecommendanaggressiveapproachtoPTMCs,while
other authors suggest that no further treatment is needed
after lobectomy or thyroidectomy. Moreover, it has even
been proposed that observation without surgical treatment
is appropriate [24].
Because the number of deaths is very small in patients
with PTMCs, in the majority of series authors use the rate of
recurrence as a marker of poor clinical outcome. Local and
regional lymph node recurrences have been observed with a
prevalence rate between 2% and 5.7% [5, 25–27].
In recent years, some speciﬁc markers for aggressiveness
have been identiﬁed [12–17]. Three of the most accepted
factors are multifocality, lymph node metastasis, and the
mode of diagnosis.
PTMCs frequently present as a multifocal process. Multi-
plefoci arereported inapproximately7%–56%ofcases[5,6,
10,28].Anumberofclinicalstudieshaveshown thatpatients
with ≥ two foci had a higher recurrence rate and cancer
mortality than those with unifocal PTMCs [5, 29]. Baudin et
al. [30] reported that only two parameters inﬂuenced PTMC
recurrences, one of which was multifocality. Moreover,
multifocality has been associated with a high incidence of
contralateral lobe involvement [31] and is an independent
risk factor for metastases [32]. Hence, multifocal PTMCs
have been considered to have a poor prognosis. In our series,
we have detected a signiﬁcantly higher rate of multifocality
in LPTCs than in PTMCs.
PTMCs also show a high incidence of regional lymph
node metastasis, occurring in 12%–64% of patients [6, 25,
33–36]. Wada et al. [37] reported that 64.1% and 44.5%
of patients have central and ipsilateral node involvement,
respectively, and two-thirds of patients have lymph node
metastasis in at least one of the two compartments. It has
been described that cases with positive lymph nodes have
a higher risk of recurrence [38]. Kim et al. [26]f o u n d
that lateral cervical node metastasis was the most powerful
independent predictor of clinical recurrence. However, other
authors have reported that the outcome of PTMCs is
favorable, even in the presence of lymph node metastases
[5, 23, 37, 39]. Prophylactic neck dissection is not routine
in our hospital; node resection was not performed in the
incidentally discovered cases. Therefore, the true number of
positive lymph nodes is unknown; however, it is interesting
to note that among patients in whom lymphadenectomy was
performed, the rate of metastasis was not diﬀerent between
PTMCs and LPTCs.
Three circumstances may lead to the detection of a
PTMC, as follows, PTMC found at autopsy, PTMC found
incidentally in specimens of the thyroid removed for
benign thyroiddisease, and clinicalPTMCs diagnosed before4 Journal of Thyroid Research
surgery [40]. Although the prevalence is highly variable,
>70% of PTMCs correspond to IPTMCs [10]. It has been
suggested that clinical and biological behaviours may diﬀer
between IPTMCs and NIPTMCs [41, 42]. Some authors
have found that overt tumors are associated with a higher
incidence of multicentricity, extrathyroidal involvement,
lymphovascular invasion, higher stage, risk of relapse, and
death [11, 42–45]. Hence, IPTMCs are associated with a
better prognosis, whereas NIPTMCs may have more aggres-
sive behavior. In like manner, we have found signiﬁcant
diﬀerences between both modes of presentation in relation
to tumor size, multifocality, and age in the group of patients
with PTMCs, whereas there were no such diﬀerences in
tumors >1cminsize.
Age is considered to be the most important prognostic
factorin PTCsandisincludedin all ofthe prognosticscoring
systems.However,someinvestigatorshavefailedtoshowthat
age aﬀects the outcome of patients with PTMCs [15, 32, 34,
38, 43, 46, 47]. It is interesting to note that in our series,
younger age is associated with a higher frequency of speciﬁc
markers for aggressiveness. Thus, older patients have more
IPTMCs without adverse markers, such as multifocality or
lymph node metastases. Moreover, the group of patients
>60 years of age has a higher incidence of cases with a
lower risk of developing later recurrences than the rest of
the patients.
In recent years, some of the molecules involved in
neoplastic transformation have been explored as markers
to assess the biological aggressiveness of PTMC [22, 48].
However, their use is at present not relevant to clinical
decision making.
In summary, PTMCs exhibit signiﬁcant diﬀerences in
presentation from LPTCs. It is possible that the classic risk
factors, which are well validated for PTCs, such as age, must
be cautiously interpreted in the current increasing subgroup
of PTMCs.
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